復星醫藥(02196.HK):控股子公司獲藥品臨牀試驗批准
格隆匯11月8日丨復星醫藥(02196.HK)公佈,近日,公司控股子公司重慶復創醫藥研究有限公司(以下簡稱"復創醫藥")收到國家藥品監督管理局關於同意其研製的FCN-342片(以下簡稱"該新藥")用於痛風治療開展臨牀試驗的批准。復創醫藥擬於條件具備後於中國大陸境內開展該新藥的I期臨牀試驗。
該新藥為集團(即公司及控股子公司/單位,下同)自主研發的URAT1抑制劑,擬主要用於痛風高尿酸血癥治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.